Navigation Links
OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
Date:3/11/2009

of the OncoGenex Web site at www.ir.oncogenex.com. Alternatively, you may access the live conference call by dialing 877-874-1569 (U.S. & Canada) or 719-325-4767 (International). A webcast replay will be available approximately two hours after the call and will be archived at the same Web location for 90 days.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information about OncoGenex is available at www.oncogenex.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning the Company's key objectives for 2009, potential results of clinical trials, the potential benefits of the Company's product candidates and other anticipated activities, achievements, occurrences and performance. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. All statements other than statements of historical fact are stateme
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014 International research and ... that its biobanking project, Provia Laboratories , has ... growing Advisory Board. Scott Wolf , CEO of ... Dr. Vaught onboard with Provia’s ever-expanding Advisory Board. His ... Provia’s management team brings to this field, should help ...
(Date:7/23/2014)... worldwide conservation efforts have made great strides in saving ... China, there are over 65 giant panda reserves that ... despite these efforts, just 1596 pandas remain in the ... zoos hope to save the panda by improving genetic ... the wild. Just how are these high-profile programs doing ...
(Date:7/23/2014)... Researchers at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), the Vienna ... Lublin have succeeded in embedding nearly perfect semiconductor ... method of producing hybrid nanowires, very fast and ... single chip in the future. The research results ... Research . , Nano-optoelectronics are considered the cornerstone ...
(Date:7/23/2014)... 23, 2014  AuraSense Therapeutics, the pioneer in developing ... regulatory and immunotherapeutic agents, announced today that ... Therapeutics, executive leadership team as chief financial ... to joining AuraSense Therapeutics, Mr. Snyder was ... of Cellular Dynamics International Inc., where he ...
Breaking Biology Technology:Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4A crystal wedding in the nanocosmos 2AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer 2
... Pharma AG today,announced that the US Food and ... (IND) application submitted by Nitec for the,initiation of ... results of a European Phase III trial (CAPRA-1;,Circadian ... dossier for marketing authorization in Europe. The FDA,s,acceptance ...
... and advantageous for the U.S. Army,s Chemical Materials Agency ... waste during regular chemical agent disposal operations, says a ... committee that wrote the report also determined that the ... the submission of data from previous trial burns -- ...
... Pacific Northwest National Laboratory,have discovered a way to ... creation of a portable biosensor that can address ... nerve agents, the need to quickly distinguish between ... , The sensor components resemble a pregnancy test ...
Cached Biology Technology:Nitec's IND Application for Clinical Development With Lodotra Accepted by the FDA 2Nitec's IND Application for Clinical Development With Lodotra Accepted by the FDA 3Report recommends off-site disposal of secondary waste 2Report recommends off-site disposal of secondary waste 3Report recommends off-site disposal of secondary waste 4Truly sick or simply scared? 2
(Date:7/23/2014)... Chrysomya megacephala is commonly found in dead ... the time of death, referred to as the post ... C. megacephala from Tamil Nadu is provided ... molecular characterization through generation of DNA barcoding. This study, ... access Biodiversity Data Journal . , Chrysomya ...
(Date:7/23/2014)... struggle to deal with ever-growing piles of electronic waste ... just how much there is and where it really ... Science & Technology , their study found that nearly ... into just seven developing countries with major potential ... Knut Breivik and colleagues note that the export from ...
(Date:7/23/2014)... sulfur-oxidizing bacterial group called SUP05 will play an increasingly ... world,s oceans as oxygen minimum zones expand, according to ... the National Academy of Sciences . , University of ... anoxic fjord, Canada,s Saanich Inlet, to chart how microbial ... "Our study paints a very detailed picture of how ...
Breaking Biology News(10 mins):Dead body feeding larvae useful in forensic investigations 2Research charts the ecological impact of microbial respiration in the oxygen-starved ocean 2
... Connie Hedegaard, the EU commissioner for Climate Action, ... new Nordic centre for Europe,s main climate innovation ... entrepreneurs, businesses, climate professionals, students and government officials ... European partnership to work on innovative solutions for ...
... and technology (S&T) eroded further during the last decade, ... their innovation capacities. According to a report released today ... body of the National Science Foundation (NSF) and an ... economies, taken together, now perform a larger share of ...
... D.C., February 6, 2014Dietary supplement users take these ... effort to develop a healthier lifestyle, according to ... , a peer-reviewed scientific publication. The review, "Health ... Nutrition Journal .2014, 13:14), co-authored by Council for ...
Cached Biology News:European Union launches Nordic climate innovation center 2European Union launches Nordic climate innovation center 3US lead in science and technology shrinking 2US lead in science and technology shrinking 3US lead in science and technology shrinking 4Scientific review points to supplement users engaging in a pattern of healthy habits 2